Proposal to list infusion devices supplied by Baxter Healthcare Limited
PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule.
What we’re proposing
PHARMAC is seeking feedback on a proposal to list medical devices supplied by Baxter Healthcare Limited (“Baxter“) in Part III of Section H of the Pharmaceutical Schedule from 1 August 2021 through a non-exclusive provisional agreement.
We propose to list medical devices in the following categories:
Consultation closes at 4pm Tuesday 29 June 2021 and feedback can be emailed to email@example.com.
What would the effect be?
From 1 August 2021, Baxter’s ranges of non-dedicated & consumable infusion devices and infusion equipment and associated devices (“infusion devices”) would be listed under a proposed national agreement (“Agreement”) that all DHBs may purchase under, subject to consultation and approval by PHARMAC’s Board or delegate.
The Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of Infusion Devices.
The Agreement would supersede any existing DHB contracts with Baxter for the devices listed in the Agreement. Any device listed in a PHARMAC Agreement and purchased by a DHB would be at the price, terms and conditions stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.
Pricing for the devices in this Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by PHARMAC.
Who we think will be interested
- DHB clinical staff in a range of different clinical settings including:
- Procurement officers and supply chain personnel
- Clinical engineers and maintenance services
- ICU, emergency, and critical care staff
- Perioperative care staff
- Nurses (both inpatient and community based)
- Infection control
- General medical ward staff
- Suppliers and wholesalers
About the infusion devices
Infusion devices are medical devices used, or associated with devices used, in the infusion of fluids such as medications, intravenous solutions (such as saline, glucose, and electrolyte solutions), blood, total parenteral nutrition (TPN) solutions into the body. This includes medical devices used in intravenous therapy as well as other infusion therapies.
PHARMAC’s infusion devices category includes:
- non-dedicated and consumable infusion devices not associated with infusion equipment; and
infusion equipment and associated devices.
Why we’re proposing this
In 2018 PHARMAC issued a Request for Proposals for:
- supply of infusion devices (including non-dedicated and consumable infusion devices and infusion equipment and associated devices)
The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
PHARMAC has been working with suppliers who responded to the RFP to seek provisional agreements. This proposal is the latest to arise from this process and we expect to consult on further provisional agreements with suppliers of infusion devices throughout 2021.
Details about our proposal
PHARMAC has entered into a provisional agreement with Baxter for the supply of infusion devices.
The proposal would result in Pharmaceutical Schedule listings for:
Number of Products
Non-dedicated and consumable infusion devices
Infusion equipment and associated devices
Further information, including pricing and contractual details, has been provided to DHB procurement personnel. Clinicians interested in further detail on what this change means for their DHB should engage with their procurement teams.
To provide feedback
Send us an email: firstname.lastname@example.org by 4pm Tuesday 29 June 2021.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Your feedback may be shared
Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.
We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.